2022 Quality Assurance Reporting Requirements (QARR)

June 30, 2022

RE: Clarification #4 for Measurement Year (MY) 2022 Updates

Dear Colleague,

This letter contains information about edits incorporated into the 2022 Quality Assurance Reporting Requirements (QARR) Technical Specifications for Measurement Year (MY) 2022 reporting. The information contained in this clarification has been incorporated into a revised version of the QARR Technical Specifications, the MY2022 PLD File Specifications, the MY2022 Value Sets, and the MY2022 Medication Lists. The updated files are posted on our Managed Care Information for Health Plans page. The revised specifications should be used in plans’ processing for MY2022 QARR.

This clarification includes the following changes made to the 2022 QARR Technical Specifications Manual:

Change Version Version Date Section(s) Changed Change Summary
4 6/30/2022 I. Submission Requirements
  • The freeze date was changed from May 15, 2022 to August 15, 2022
  • Added COVID-19 Immunization Status to New Measures
  • Removed Annual Dental Visit requirement for Essential Plans
  • Updated the contact for IPRO's FTP management
  • Changed live birth files deadline to a business day
II. Table 1. QARR List of Required Measures
  • Added COVID-19 Immunization Status for Commercial and Medicaid product lines
  • Modified Annual Dental Visit to be Not Required for the EP product line
  • Added a flag to Colorectal Cancer Screening indicating that the Medicaid line of business requires the administrative method
III. Audit Requirements Changed audit file due dates to business days
IV. Reporting Schedule
  • Changed audit file agreement to a business day
  • Updated the IPRO contact
V. New York State Specific Measures Added COVID-19 Immunization Status
VI. Patient-Level Detail and NYS- Specific Measures Summary-Level File Submission
  • Added COVID-19 Immunization Status for Commercial and Medicaid lines of business
  • Removed requirement for ADV for Commercial line of business
  • Removed the requirement to include colorectal cancer screening in the NYS-Specific Measures Summary-Level File
Multiple
  • Changed the names of measures to reflect HEDIS name changes (Follow-Up After Emergency Department Visit for Substance Use (FUA) and Initiation and Engagement of Substance Use Disorder Treatment (IET)
  • Change the name of Use of Pharmacotherapy for Alcohol Abuse or Dependence to Use of Pharmacotherapy for Alcohol Use or Dependence (POA)
Patient-Level Detail File
  • Commercial PLD:
  • Removed colorectal cancer screening and colorectal cancer screening electronic measures from the original location (COL and COL-E)
  • Added colorectal cancer screening measures with new-age stratifications (COL and COL-E)
  • Removed Annual Dental Visit requirement (ADV)
  • Added Covid-19 Vaccine Immunization Status
  • Removed references to abuse with new terminology (e.g., Alcohol Abuse replaced with Alcohol Use Disorder)
  • Medicaid PLD
    • o Removed colorectal cancer screening and colorectal cancer screening electronic measures from the original location (COL and COL-E)
  • Added colorectal cancer screening measures with new-age stratifications (COL and COL-E)
  • Added Covid-19 Vaccine Immunization Status
  • Removed references to abuse with new terminology (e.g., Alcohol Abuse replaced with Alcohol Use Disorder)
  • Exchange PLD o Removed colorectal cancer screening measure from the original location (COL) o Added colorectal cancer screening measure with new-age stratifications (COL) o Removed references to abuse with new terminology (e.g., Alcohol Abuse replaced with Alcohol Use Disorder)
Value Sets Updated the value sets to align with changes to HEDIS
Medication Lists Updated the medication list to align with changes to HEDIS

If there are any questions about the above edits, or if you find issues or have concerns with the 2022 Technical Specifications manual or other documents, please email nysqarr@health.ny.gov.

Sincerely,

Paloma Luisi, MPH
Director, Bureau of Quality Measurement & Evaluation
Center for Applied Research and Evaluation
Office of Quality and Patient Safety

CC: M.B. Conroy
       R. Josberger
       M. Lurie